Browse by Medical Category
Accepting New Patients: Call for Availability
Go To Programs
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Kenneth A. Freedberg, MD, is Professor of Medicine at Harvard Medical School and Massachusetts General Hospital and Director of the Program in Epidemiology and Outcomes Research at the Harvard University Center for AIDS Research (CFAR). He also directs the Medical Practice Evaluation Center within the Department of Medicine at Massachusetts General Hospital.
Dr. Freedberg's research interests focus on HIV, TB, as well as other chronic disease clinical outcomes and health policy, utilizing the methods of comparative effectiveness, cost-effectiveness analysis, clinical epidemiology, and implementation science. He is most interested in the intersection of clinical medicine and economics - to understand the "value" of health care.
His current research efforts are focused in the United States, France, Portugal, Brazil, South Africa, Cote d'Ivoire, Zimbabwe, Botswana, Mozambique and India. This NIH and foundation-funded work examines clinical policies for antiretroviral use, HIV testing, laboratory management, and HIV/TB co-infection.
The Medical Practice Evaluation Center team has a particular interest in informing guidelines in individual countries and across regions in both well-resourced and resource-limited settings. Collaborators include investigators in each of the countries above, as well as in HIV trials groups in the United States including the ACTG, IMPAACT, and the HPTN.
View my most recent publications at PubMed
As study led by a Massachusetts General Hospital research team finds that an HIV treatment regimen widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India and reduce the number of new HIV infections with minimal impact on the country’s HIV/AIDS budget.
An analysis led by a team of Massachusetts General Hospital investigators shows that achieving the treatment targets of the National HIV/AIDS Strategy by 2020 not only would prevent hundreds of thousands of new infections and deaths but also would demonstrate excellent value.
"Treatment as prevention" – early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission – appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission.
Eliminating new infant HIV infections in Zimbabwe will require not only improved access to antiretroviral medications but also support to help HIV-infected mothers continue taking their medication and safely reduce or eliminate breastfeeding, according to study led by MGH investigators.
MGH Hotline 010909
Andrea Ciaranello, MD, MPH, of the MGH Infectious Disease Unit; and Kenneth A. Freedberg, MD, MSc, director of the MGH HIV Research Program in the Division of General Medicine, have received a grant from the Elizabeth Glaser Pediatric AIDS Foundation to study best practices in the fight against pediatric AIDS.
Back to Top